Literature DB >> 6327306

Target size analysis and molecular properties of Ca2+ channels labelled with [3H]verapamil.

A Goll, D R Ferry, H Glossmann.   

Abstract

[3H]Verapamil was employed to label the drug receptor sites within the Ca2+-channel in skeletal muscle microsomes which are coupled in a negative heterotropic allosteric manner to the previously characterized 1,4-dihydropyridine receptors. At 2 degrees C the Kd of a high-affinity receptor site is 45 nM and the maximum density of binding sites is 37 pmol/mg of protein. Established subcellular fractionation procedures were used to isolate transverse tubule membranes from rabbit and guinea-pig skeletal muscle. [3H]Verapamil, d-cis-[3H]diltiazem as well as 1,4-[3H]dihydropyridine receptors copurify with t-tubule membranes. The ratio of high-affinity verapamil: 1,4-dihydropyridine d-cis-diltiazem Ca2+ channel receptor sites is 4:2:1. The verapamil drug receptors are heat-labile and have essential sulfhydryl groups since they are inactivated by p-chloromercuriphenylsulfonic acid and N-ethylmaleimide. The receptors recognize the main classes of Ca2+ antagonists and agonists in a stereoselective manner. Divalent cations (Mn2+ greater than Ca2+ greater than Mg2+) are inhibitory. Target size analysis with high-energy electrons was performed and the Mr of the verapamil drug receptor site is 110000.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6327306     DOI: 10.1111/j.1432-1033.1984.tb08172.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  13 in total

1.  Extra- and intracellular action of quaternary devapamil on muscle L-type Ca(2+)-channels.

Authors:  S Berjukov; S Aczel; B Beyer; S D Kimball; M Dichtl; S Hering; J Striessnig
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

Review 2.  The molecular pharmacology and structural features of calcium channels.

Authors:  D R Ferry; A Goll; M Rombusch; H Glossmann
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

3.  High affinity interaction of mibefradil with voltage-gated calcium and sodium channels.

Authors:  P Eller; S Berjukov; S Wanner; I Huber; S Hering; H G Knaus; G Toth; S D Kimball; J Striessnig
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

4.  Ontogenesis and localization of Ca2+ channels in mammalian skeletal muscle in culture and role in excitation-contraction coupling.

Authors:  G Romey; L Garcia; V Dimitriadou; M Pincon-Raymond; F Rieger; M Lazdunski
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

Review 5.  Calcium channels: molecular pharmacology, structure and regulation.

Authors:  M M Hosey; M Lazdunski
Journal:  J Membr Biol       Date:  1988-09       Impact factor: 1.843

6.  Relationship between the stereoselective negative inotropic effects of verapamil enantiomers and their binding to putative calcium channels in human heart.

Authors:  D R Ferry; H Glossmann; A J Kaumann
Journal:  Br J Pharmacol       Date:  1985-04       Impact factor: 8.739

7.  Correlation between the negative inotropic potency and binding parameters of 1,4-dihydropyridine and phenylalkylamine calcium channel blockers in cat heart.

Authors:  A Goll; H Glossmann; R Mannhold
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-11       Impact factor: 3.000

8.  (-)-3H-desmethoxyverapamil labelling of putative calcium channels in brain: autoradiographic distribution and allosteric coupling to 1,4-dihydropyridine and diltiazem binding sites.

Authors:  D R Ferry; A Goll; C Gadow; H Glossmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-09       Impact factor: 3.000

9.  Partial purification of a protein from maize (Zea mays) coleoptile membranes binding the Ca2+-channel antagonist verapamil.

Authors:  H J Harvey; M A Venis; A J Trewavas
Journal:  Biochem J       Date:  1989-01-01       Impact factor: 3.857

10.  Competitive action of divalent cations and D600 in frog slow muscle fibers.

Authors:  P Krippeit-Drews; H Schmidt
Journal:  J Membr Biol       Date:  1989-12       Impact factor: 1.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.